Cybin (TSE:CYBN) has released an update.
Cybin Inc., a biopharmaceutical company focused on developing psychedelic-based treatments, has announced the appointment of Dr. Atul Mahableshwarkar as Senior Vice President, Clinical Development. Dr. Mahableshwarkar is set to steer the Phase 3 study of CYB003, Cybin’s psilocybin analog for treating major depressive disorder, which has been designated as a Breakthrough Therapy by the FDA. His extensive experience in drug development and clinical trials aims to accelerate Cybin’s mission to transform mental healthcare.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
